Comparison of antimouse and antihorse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin

C. F. Shield; D. J. Norman; P. Marlett; A. J. Fucello; G. Goldstein

Comparison of antimouse and antihorse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin

C. F. Shield, D. J. Norman, P. Marlett, A. J. Fucello, G. Goldstein

Research output: Contribution to journal › Article › peer-review

Abstract

Antimouse antibody is produced from 40 to 68% of the time after administration of Orthoclone OKT3. In patients treated with OKT3, however, if the concomitant immunosuppression is not decreased, the incidence of the antibody production is reduced to 40%. Similarly, 33% of patients developed antihorse antibody after the initial antithymocyte globulin (ATG) administration. Most of the time, the antibody production is low-titered for both OKT3 and ATG.

Original language	English (US)
Pages (from-to)	48-51
Number of pages	4
Journal	Nephron
Volume	46
Issue number	SUPPL. 1
State	Published - 1987
Externally published	Yes

ASJC Scopus subject areas

Physiology
Nephrology
Urology
Physiology (medical)

Cite this

@article{c1f25ae29f4740cf969812f01a903e0b,

title = "Comparison of antimouse and antihorse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin",

abstract = "Antimouse antibody is produced from 40 to 68% of the time after administration of Orthoclone OKT3. In patients treated with OKT3, however, if the concomitant immunosuppression is not decreased, the incidence of the antibody production is reduced to 40%. Similarly, 33% of patients developed antihorse antibody after the initial antithymocyte globulin (ATG) administration. Most of the time, the antibody production is low-titered for both OKT3 and ATG.",

author = "Shield, {C. F.} and Norman, {D. J.} and P. Marlett and Fucello, {A. J.} and G. Goldstein",

year = "1987",

language = "English (US)",

volume = "46",

pages = "48--51",

journal = "Nephron",

issn = "0028-2766",

publisher = "S. Karger AG",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Comparison of antimouse and antihorse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin

AU - Shield, C. F.

AU - Norman, D. J.

AU - Marlett, P.

AU - Fucello, A. J.

AU - Goldstein, G.

PY - 1987

Y1 - 1987

N2 - Antimouse antibody is produced from 40 to 68% of the time after administration of Orthoclone OKT3. In patients treated with OKT3, however, if the concomitant immunosuppression is not decreased, the incidence of the antibody production is reduced to 40%. Similarly, 33% of patients developed antihorse antibody after the initial antithymocyte globulin (ATG) administration. Most of the time, the antibody production is low-titered for both OKT3 and ATG.

AB - Antimouse antibody is produced from 40 to 68% of the time after administration of Orthoclone OKT3. In patients treated with OKT3, however, if the concomitant immunosuppression is not decreased, the incidence of the antibody production is reduced to 40%. Similarly, 33% of patients developed antihorse antibody after the initial antithymocyte globulin (ATG) administration. Most of the time, the antibody production is low-titered for both OKT3 and ATG.

UR - http://www.scopus.com/inward/record.url?scp=0023215605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023215605&partnerID=8YFLogxK

M3 - Article

C2 - 3306425

AN - SCOPUS:0023215605

SN - 0028-2766

VL - 46

SP - 48

EP - 51

JO - Nephron

JF - Nephron

IS - SUPPL. 1

ER -

Comparison of antimouse and antihorse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this